常用名 | (S)-2-甲氧基-3-[4-[2-(5-甲基-2-苯基恶唑-4-基)乙氧基]苯并[B]噻吩-7-基]丙酸 | CAS号 | 475479-34-6 |
---|---|---|---|
价格 | 纯度 | 99.0% | |
备货期 | 10天 | 库存 | 现货 |
产品详情(用途,包装等)
用途: Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ)Target: PPARα/γAleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones. 物理化学性质: CAS号:475479-34-6 常用中文名:(S)-2-甲氧基-3-[4-[2-(5-甲基-2-苯基恶唑-4-基)乙氧基]苯并[B]噻吩-7-基]丙酸 常用英文名:Aleglitazar 分子式:C24H23NO5S 分子量:437.50800 密度:1.29 沸点:665.151ºC at 760 mmHg 熔点:N/A 闪点:356.071ºC 储存条件:2-8℃ |